After sequencing, we identified a novel homozygous nonsense variant c.100G > T / p.Gly34* in SLC10A7 (NM_032128.4), which was inherited from her parents. This variant has not been reported in the dbSNP, 1000 genome, ESP, ExAC, or gnomAD databases, which indicates that it is rare in the normal population, neither not been previously reported in patients with SSASKS (Fig. 2A, Supplementary Table 1). It is located at the end of exon 1 of SLC10A7, and leads to the premature SLC10A7 protein. Therefore, we classified this nonsense variant as a pathogenic variant according to the ACMG/AMP guidelines.
Fig. 2Schematic diagram of SLC10A7 protein and function. (A) Distribution of 12 reported variants. Nonsense variant of our case was labeled in red. (B,C) Predicted 3D structure of SLC10A7 protein. It was predicted using AphlaFold2 (https://www.alphafold.ebi.ac.uk/), and depicted using PyMOL (https://www.pymol.org). (B) Lateral side of protein. (C) Top side of protein depicted from luminal side. (D) SLC10A7 as a negative regulator of Ca2+ hemostasis by inhibiting Orai1 and SERCA. After GPCR activation, PLC hydrolyses PIP2 to IP3. The latter binds to IP3R and leads to depletion of ER Ca2+ store. ER Ca2+ sensor STIM1 oligomerizes and recruits Orai1 to ER-PM junction and stimulates Orai1-operated Ca2+ influx. Then, ER Ca2+ store is refilled by SERCA pumping cytoplasmic Ca2+ into ER. SLC10A7 could inhibit the STIM1, Orai1 and SERCA to negatively regulate Ca2+ uptake, thus SSASKS-causing SLC10A7 mutations increase Ca2+ influx. Abbreviations, TM, trans-membrane; N-term, N termination of protein; C-term, C termination of protein; GPCR, G protein-coupled receptors; PLC, phospholipase C; PIP2, phosphatidylinositol (4, 5) bisphosphate (PI (4, 5) P2); IP3, inositol triphosphate; IP3R, IP3 receptor; SERCA2, sarcoplasmic/endoplasmic reticulum calcium ATPase 2
Our patient had a relatively severe and broad clinical phenotype compared with previously reported cases (Supplementary Table 1). Similar to other cases of SSASKS, she had a short stature, type III hypocalcified amelogenesis imperfecta [2], and skeletal dysplasia characterized by short long bones, abnormal hands, progressive scoliosis, hyperlordosis, and kyphosis. Unlike other patients, both of her vision and hearing were compromised, and a wide inner diameter of the aortic sinus and patent foramen ovale were also found. Although no neurodevelopmental delay was observed to date, long-term follow-up and close attention are required. The patient received seven surgeries, which comprised rod implantation twice, lengthening four times, and final fusion once. Timely surgeries and regular check-ups effectively controlled the progression of scoliosis and possible kyphosis, and avoided implant-related complications [4]. Although there was limited growth potential of the spine in our patient with SSASKS, four lengthening surgeries helped to increase the patient’s height by 2.4 cm.
SSASKS is an extremely rare autosomal recessive disorder, which mainly affects the skeletal system. Because of characteristic abnormal N-glycosylation of the protein or lipid and overlapping skeletal defects, SSASKS was identified as a subtype of congenital disorders of glycosylation [5]. Part of patients with SSASKS have developmental delay in the intrauterine and postnatal periods which characterized by a short stature. Amelogenesis imperfecta, characterized by hypomineralized and discolored enamel [6], is a distinguishing feature of patients with SSAKS. Skeletal dysplasia can also affect the spine, limbs, hands and feet, and related joints. Irregular vertebral formation can lead to progressive scoliosis, hyperlordosis, or kyphoscoliosis. The limbs in these patients have short long bones, a distinct appearance of “Swedish key”, and abnormal epiphyses. The affected joints are hypermobile, and patients have knee dislocations, coxa valga, genua valga, and pes planus. Radiographs show advanced carpal and/or tarsal ossification of patients with SSASKS. Variable features include intellectual developmental impairment, facial dysmorphism, and hearing and visual impairment. Some of these patients can have a flat face, micrognathia, retrognathia, blue sclerae, hypertelorism, prominent eyes, and ptosis (Supplementary Table 1). In 2018, the first group of patients with SSASKS was identified, and this condition was related to SLC10A7 mutation and secondary glucosaminoglycan (GAG) biosynthesis defects [7]. These defects include overrepresented high-mannose-type N-glycans, which is only composed of N-acetylglucosamine and mannose residues, and decreased sialylated complex-type (mature) N-glycans. To date, there have only been 12 cases of SSASKS reported worldwide (Fig. 2A, Supplementary Table 1) [1, 8].
SLC10A7 transporter is located at the compartments of the secretory pathway, including the endoplasmic reticulum (ER), Golgi, and plasma membrane (PM) in homodimers [9]. SLC10A7 was first sequenced by Zou et al. who named it C4orf13 [10]. SLC10A7 has 10 possible TM domains and a putative O-linked glycosylation site (Fig. 2B, C), and both N and C termination of SLC10A7 are toward the cytosolic side [10]. Similar to its homolog from Yersinia frederiksenii (ASBTYf) [11, 12] and Neisseria meningitidis (ASBTNM) [13], SLC10A7 contains a typical sodium/bile acid cotransporter family (SBF) domain as other members of the SLC10 family, with a core ion-binding site (Fig. 2B, C, gray area II) and an organic compound-transporting site (Fig. 2B, C, gray area I, between TM4 and TM9) [14]. However, SLC10A7 is not conserved with sequences of characteristic Na+ binding sites of bacterial ASBTYf, human SLC10A1, and SLC10A2, and SLC10A7 does not transport bile acid or Na+ [14]. As an orphan solute carrier, which ion and organic compounds SLC10A7 transports are unknown.
SLC10A7 is ubiquitously expressed [15], and it is highly expressed in cartilages differentiating into long bones and growth plates [7]. In addition, in situ hybridization labeling in mouse fetuses and RT-PCR have shown precise spatiotemporal expression of Slc10a7 in the teeth, vertebrae, and long bones. From embryonic day 14.5 (E14.5), Slc10a7 expression is present at the epithelial compartment of the tooth cap stage. At E16.5, Slc10a7 expression is found in the inner dental epithelium and in the epithelial loop of bell stage teeth. At E18.5, Slc10a7 expression is present in the inner dental epithelium of the incisors and in ameloblasts and odontoblasts of the molars. During the process of ossification, vertebrae at E16.5 and E18.5, and the humerus and femur at E16.5 show Slc10a7 expression [8, 16]. These findings suggest an important role of SLC10A7 in mineralization and ossification of the teeth, vertebrae, and long bones.
SLC10A7 transports glycoproteins from the post-Golgi compartment to the cell PM, and mediates bone mineralization [1]. Patients with SSASKS have a shift in the N-glycoprotein pattern, including increased high-mannose glycans and glycans lacking GlcNAc, and decreased sialylated glycans [7, 17]. SiaNAl labeling and pulse-chase labeling in fibroblasts of patients with SSASKS showed abnormal accumulation of sialylated glycoconjugates compared with healthy controls [17]. Zebrafish and a mouse model recapitulated the human phenotype of SSASKS. High-dose morpholino-induced SLC10A7-deficient zebrafish show a considerable reduction in bone mineralization at a nearly undetectable level [1]. A previous study showed that the Slc10a7−/− mouse displayed a rounded skull, short long bones, disorganized growth plate, and hypomineralized AI [7]. Safranin O and Masson’s trichrome staining of the distal femur epiphysis showed disorder in the growth plates. The proliferative zone was thinner in the Slc10a7−/− mouse owing to tightly packed chondrocytes. The pre-hypertrophic/hypertrophic zone was the most affected, and the hypertrophic layer was only limited to irregularly aligned two- to three-cell tiers. At the same time, stronger blue staining of collagen fibers was observed in the growth plates of Slc10a7−/− mice than that in the wild type. This finding suggests an altered composition of the extracellular matrix, possibly due to a decreased proteoglycan/collagen ratio, leading to disorganization of the growth plate and a delay in bone growth. Patients with SSASKS and the Slc10a7−/− mouse have a reduced proportion of heparan sulfates in total GAG, which suggests a defect in GAG synthesis because of SLC10A7 deficiency [7]. Therefore, SLC10A7 deficiency leads to abnormal Golgi glycosylation and a defect in GAG synthesis, including intracellular mis-localization of glycoproteins, a defect in post-Golgi transport of glycoproteins to the cell PM, and a reduced proportion of heparan sulfates.
SLC10A7 also negatively regulates cellular calcium hemostasis, and the pathogenic SLC10A7 variant can reduce cellular calcium influx [8, 18]. Previous studies have shown that CaRch1 and ScRch1, which are two homologs of SLC10A7 in Candida albicans [19, 20] and Saccharomyces cerevisiae [21], function as regulators of cytosolic Ca2+ homeostasis and are regulated by the calcium/calcineurin signaling pathway. Fibroblasts in SLC10A7-deficienct patients show higher extracellular Ca2+ levels than those in healthy controls [7]. Two disease-causing missense variants (P303L and L74P) transfecting HEK293 cells also show higher Ca2+ influx levels than wild-type controls [18]. SLC10A7 negatively regulates Ca2+ influx by interacting with store-operated calcium entry (SOCE) and/or sarcoplasmic/ER calcium ATPase 2 (SERCA2) [9]. Extracellular ATP initiates G protein-coupled receptor (GPCR) to activate phospholipase C (PLC), which catalyzes phosphatidylinositol 4,5-diphosphate2 (PIP2) into inositol triphosphate (IP3). IP3 receptor (IP3R), which is located at the ER, interacts with IP3 and transports ER luminal Ca2+ into the cytosol. Stromal interaction molecule 1 (STIM1) senses a reduction of Ca2+ in the ER and recruits Orai1 from the PM to the PM-ER junction and activates Orai1-mediated Ca2+ influx. Finally, SERCA2 at the ER pumps Ca2+ from the cytosol to the ER lumen and restores Ca2+ levels in the ER (Fig. 2D). SLC10A7 can inhibit STIM1, Orai1, and SERCA2 to negatively regulate intracellular calcium signaling, and this might be involved in Golgi glycosylation and GAG synthesis mentioned above.
Comments (0)